Browsing by Author "Sebastián Mondaca"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial
    (2020) María Elvira Balcells; Luis Rojas; Nicole Le Corre; Constanza Martínez-Valdebenito; María Elena Ceballos; Marcela Ferrés; Mayling Chang; Cecilia Vizcaya; Sebastián Mondaca; Álvaro Huete; Ricardo Castro; Mauricio Sarmiento; Luis Villarroel; Alejandra Pizarro; Patricio Ross; Jaime Santander; Barbara Lara; Marcela Ferrada; Sergio Vargas-Salas; Carolina Beltrán-Pavez; Ricardo Soto-Rifo; Fernando Valiente-Echeverría; Christian Caglevic; Mauricio Mahave; Carolina Selman; Raimundo Gazitúa; José Luis Briones; Franz Villarroel-Espindola; Carlos Balmaceda; Manuel A. Espinoza; Jaime Pereira; Bruno Nervi
  • Thumbnail Image
    Item
    High proportion of potential candidates for immunotherapy in a Chilean cohort of gastric cancer patients: results of the FORCE1 study
    (2019) Cordova-Delgado, Miguel; Mauricio P. Pinto; Ignacio N. Retamal; Matías Muñoz-Medel; María Loreto Bravo; María F. Fernández; Betzabé Cisternas; Sebastián Mondaca; César Sanchez; Hector Galindo; Bruno Nervi; Carolina Ibáñez; Francisco Acevedo; Jorge Madrid; José Peña; Erica Koch; Maria José Maturana; Diego Romero; Nathaly de la Jara; Javiera Torres; Manuel Espinoza; Carlos Balmaceda; Yuwei Liao; Zhiguang Li; Matías Freire; Valentina Gárate-Calderón; Javier Cáceres; Gonzalo Sepúlveda-Hermosilla; Rodrigo Lizana; Liliana Ramos; Rocío Artigas; Enrique Norero; Fernando Crovari; Ricardo Armisén; Alejandro H. Corvalán; Gareth I. Owen; Marcelo Garrido
    Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients.